NCT05527301View on ClinicalTrials.gov

HEM1036 Phase 2 Study in Low Anterior Resection Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

January 1, 2026

Study Completion Date

January 1, 2026

Conditions
LARS - Low Anterior Resection Syndrome
Interventions
DRUG

Lactobacillus Fermentum

Lactobacillus Fermentum

DRUG

Placebo

Placebo

Sponsors

Lead Sponsor

HEM Pharma Inc.
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

HEM Pharma Inc.

INDUSTRY

NCT05527301 - HEM1036 Phase 2 Study in Low Anterior Resection Syndrome | Biotech Hunter | Biotech Hunter